Development of Medical Countermeasures to Chemical Terrorism—The NIEHS’s Involvement in a Government-Wide Research Effort by unknown
T
he attacks of September 11, 2001, using airplanes, followed closely by
the biologic attacks using anthrax spores placed in letters, have
illustrated how vulnerable our society is to such acts of terrorism. Since
these events, the NIH has led the national research effort focused on the
development of medical countermeasures to treat civilian mass casualties.
The NIH has received more than $1.5 billion annually, starting in
FY 2002, to fund research focused primarily on development of products
to diagnose, treat, or prevent bacterial and viral infectious diseases and
toxemias that could result from bioterrorist attacks. These initial efforts,
focused on infectious agents, have been led by the National Institute of
Allergy and Infectious Diseases. In FY 2005, the NIH was given an
additional $47.1 million to establish a radiation and nuclear medical
countermeasures program to identify products to treat civilians injured by a
dirty bomb or nuclear attack. Similar plans are under way to initiate
research in FY 2006 to develop products to diagnose and treat victims of a
chemical attack.
As part of the planning for an expanded effort related to chemical
agents, the NIEHS and the National Institute on Neurological Diseases
and Stroke co-sponsored, in FY 2005, an administrative supplement
program to existing grants. The intent of these supplements is to develop
improved detection, diagnosis, and treatment strategies for likely chemical
threat agents. As a result of this program, NIEHS has funded six supple-
ments for a total of $450,000. The NIEHS supplements went to:
»Paul Bishop and Joseph Caruso, University of Cincinnati, to
work on increasing the sensitivity of methods they have devel-
oped for detecting hydrolysis products of nerve agents and to
extend their analysis to spiked food and water samples
»Brian Day, National Jewish Medical and Research Center, to test the ability of lipoic acid, dihydrolipoic acid,
and thioredoxin to reverse or prevent pulmonary injury caused by sulfur mustard
»Richard DiGiulio and Ted Slotkin, Duke University, to study the developmental neurotoxicity of nerve
agents and to assess some possible protective treatment strategies
»Clem Furlong, University of Washington, to attempt to increase the activity of human PON1 enzyme to levels
sufficient to protect against paraoxon exposure in a mouse model. If successful, he will test the modified enzyme’s
ability to protect against exposure to sarin, soman, and VX agents in the same mouse model.
»Bruce Hammock and Ian Kennedy, University of California, Davis, to work on the development of miniatur-
ized sensors for use in detecting botulinum toxin, ricin, and abrin
»Cary Pope, Oklahoma State University, to study the differential toxicity of the organophosphorus pesticides
chlorpyrifos and parathion, as well as the threat agents sarin and soman, and their inhibition of acetyl-
cholinesterase and the accumulation of acetylcholine in a cannulated rat brain model
This administrative supplement program for selected grant mechanisms funded by NIEHS has just been reannounced for 
FY 2006 in the NIH Guide (http://grants.nih.gov/grants/guide/notice-files/NOT-ES-06-001.html).
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